triple glp-1/gip/glucagon receptor agonist Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Retatrutide vs Tirzepatide π¬ What's
Description
10.1124/pr.108.000604 51 KimuraI.IchimuraA.Ohue-KitanoR.IgarashiM
The triple agonist approach creates what researchers describe as a metabolic triple threat
The market benefits from the early adoption of new therapies and broad insurance coverage
References Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L et al (2018) Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome
Surgery for Obesity and Related Diseases
